Trial Outcomes & Findings for Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) (NCT NCT00546572)
NCT ID: NCT00546572
Last Updated: 2011-07-14
Results Overview
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
938 participants
Primary outcome timeframe
1 month after Vax 1 / Year 0
Results posted on
2011-07-14
Participant Flow
Participant milestones
| Measure |
13vPnC / 13vPnC
13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliters (mL) dose intramuscularly (IM) at Year 0 (vaccination 1 \[Vax 1\]) and 13vPnC 0.5 mL IM at Year 1 (Vax 2)
|
23vPS / 13vPnC
23-valent pneumococcal polysaccharide conjugate vaccine (23vPS) 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL IM at Year 1 (Vax 2)
|
|---|---|---|
|
Vax 1 / Year 0
STARTED
|
464
|
474
|
|
Vax 1 / Year 0
Received Vax 1
|
463
|
473
|
|
Vax 1 / Year 0
COMPLETED
|
391
|
404
|
|
Vax 1 / Year 0
NOT COMPLETED
|
73
|
70
|
|
Vax 2 / Year 1
STARTED
|
391
|
404
|
|
Vax 2 / Year 1
Received Vax 2
|
391
|
404
|
|
Vax 2 / Year 1
COMPLETED
|
387
|
402
|
|
Vax 2 / Year 1
NOT COMPLETED
|
4
|
2
|
Reasons for withdrawal
| Measure |
13vPnC / 13vPnC
13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliters (mL) dose intramuscularly (IM) at Year 0 (vaccination 1 \[Vax 1\]) and 13vPnC 0.5 mL IM at Year 1 (Vax 2)
|
23vPS / 13vPnC
23-valent pneumococcal polysaccharide conjugate vaccine (23vPS) 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL IM at Year 1 (Vax 2)
|
|---|---|---|
|
Vax 1 / Year 0
Randomized, not treated
|
1
|
1
|
|
Vax 1 / Year 0
Withdrawal by Subject
|
3
|
2
|
|
Vax 1 / Year 0
Protocol Violation
|
3
|
4
|
|
Vax 1 / Year 0
Death
|
2
|
2
|
|
Vax 1 / Year 0
Adverse Event
|
0
|
1
|
|
Vax 1 / Year 0
Lost to Follow-up
|
0
|
1
|
|
Vax 1 / Year 0
6-Month Contact; withdraw before Vax 2
|
64
|
59
|
|
Vax 2 / Year 1
Other
|
1
|
1
|
|
Vax 2 / Year 1
Adverse Event
|
1
|
0
|
|
Vax 2 / Year 1
Vax 2; withdraw before 6-Month Contact
|
2
|
1
|
Baseline Characteristics
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Baseline characteristics by cohort
| Measure |
13vPnC
n=463 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=473 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
Total
n=936 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age Continuous
|
76.7 years
STANDARD_DEVIATION 4.6 • n=5 Participants
|
76.7 years
STANDARD_DEVIATION 4.5 • n=7 Participants
|
76.7 years
STANDARD_DEVIATION 4.6 • n=5 Participants
|
|
Sex: Female, Male
Female
|
221 Participants
n=5 Participants
|
235 Participants
n=7 Participants
|
456 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
242 Participants
n=5 Participants
|
238 Participants
n=7 Participants
|
480 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 1 month after Vax 1 / Year 0Population: Evaluable Immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate OPA antibody titer to the given serotype.
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Outcome measures
| Measure |
13vPnC
n=426 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=445 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 3
|
55 geometric mean titer
Interval 47.7 to 62.9
|
49 geometric mean titer
Interval 42.9 to 56.9
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 4
|
545 geometric mean titer
Interval 441.9 to 672.3
|
203 geometric mean titer
Interval 157.1 to 262.2
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 5
|
72 geometric mean titer
Interval 59.7 to 86.6
|
36 geometric mean titer
Interval 29.5 to 43.1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 6B
|
1261 geometric mean titer
Interval 1024.7 to 1552.6
|
417 geometric mean titer
Interval 330.5 to 526.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 7F
|
245 geometric mean titer
Interval 191.9 to 312.4
|
160 geometric mean titer
Interval 123.5 to 207.9
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 9V
|
181 geometric mean titer
Interval 138.0 to 237.0
|
90 geometric mean titer
Interval 67.8 to 119.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 14
|
280 geometric mean titer
Interval 227.5 to 345.5
|
285 geometric mean titer
Interval 228.9 to 354.3
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 18C
|
907 geometric mean titer
Interval 761.9 to 1080.1
|
481 geometric mean titer
Interval 385.1 to 600.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 19F
|
333 geometric mean titer
Interval 273.2 to 404.8
|
214 geometric mean titer
Interval 174.3 to 262.8
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 23F
|
158 geometric mean titer
Interval 126.0 to 198.6
|
43 geometric mean titer
Interval 34.2 to 53.5
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 1
|
81 geometric mean titer
Interval 68.4 to 95.9
|
55 geometric mean titer
Interval 46.2 to 64.8
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Serotype 19A
|
354 geometric mean titer
Interval 307.7 to 408.4
|
200 geometric mean titer
Interval 170.0 to 234.4
|
PRIMARY outcome
Timeframe: Baseline, 1 month after Vax 1 / Year 0Population: Evaluable Immunogenicity population. N=number of participants with a determinate antibody titer to the given serotype.
OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.
Outcome measures
| Measure |
13vPnC
n=408 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=411 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
|
71.1 observed percentage of participants
Interval 66.4 to 75.4
|
27.3 observed percentage of participants
Interval 23.0 to 31.8
|
SECONDARY outcome
Timeframe: 1 month after Vax 1 / Year 0Population: Evaluable Immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.
Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.
Outcome measures
| Measure |
13vPnC
n=421 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=433 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
|
903 geometric mean titer
Interval 726.7 to 1121.3
|
94 geometric mean titer
Interval 74.1 to 118.5
|
SECONDARY outcome
Timeframe: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1Population: Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype at both the postvaccination 1 and postvaccination 2 blood draws.
Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Outcome measures
| Measure |
13vPnC
n=361 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=361 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 3
|
55 geometric mean titer
Interval 47.2 to 64.0
|
55 geometric mean titer
Interval 48.4 to 63.1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 23F
|
167 geometric mean titer
Interval 130.9 to 213.0
|
309 geometric mean titer
Interval 251.6 to 380.1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 1
|
79 geometric mean titer
Interval 65.3 to 94.6
|
76 geometric mean titer
Interval 64.8 to 89.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 4
|
614 geometric mean titer
Interval 489.8 to 768.8
|
487 geometric mean titer
Interval 393.9 to 603.3
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 5
|
69 geometric mean titer
Interval 56.2 to 84.2
|
57 geometric mean titer
Interval 46.9 to 68.5
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 6A
|
971 geometric mean titer
Interval 771.0 to 1222.1
|
1169 geometric mean titer
Interval 974.0 to 1403.0
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 6B
|
1358 geometric mean titer
Interval 1085.4 to 1700.2
|
1590 geometric mean titer
Interval 1316.9 to 1919.8
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 7F
|
222 geometric mean titer
Interval 170.2 to 290.2
|
180 geometric mean titer
Interval 138.1 to 233.8
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 9V
|
187 geometric mean titer
Interval 139.3 to 250.4
|
166 geometric mean titer
Interval 124.2 to 220.8
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 14
|
265 geometric mean titer
Interval 209.9 to 333.6
|
241 geometric mean titer
Interval 194.4 to 299.1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 18C
|
918 geometric mean titer
Interval 763.4 to 1104.3
|
1003 geometric mean titer
Interval 850.2 to 1182.1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 19A
|
349 geometric mean titer
Interval 299.7 to 405.5
|
341 geometric mean titer
Interval 297.2 to 390.5
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Serotype 19F
|
329 geometric mean titer
Interval 265.6 to 408.6
|
322 geometric mean titer
Interval 266.3 to 389.6
|
SECONDARY outcome
Timeframe: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1Population: Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype.
Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Outcome measures
| Measure |
13vPnC
n=370 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=445 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 5
|
56 geometric mean titers
Interval 46.6 to 67.7
|
36 geometric mean titers
Interval 29.5 to 43.1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 6B
|
1565 geometric mean titers
Interval 1306.1 to 1875.9
|
417 geometric mean titers
Interval 330.5 to 526.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 7F
|
185 geometric mean titers
Interval 142.9 to 239.7
|
160 geometric mean titers
Interval 123.5 to 207.9
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 9V
|
158 geometric mean titers
Interval 119.5 to 209.5
|
90 geometric mean titers
Interval 67.8 to 119.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 14
|
238 geometric mean titers
Interval 192.3 to 293.8
|
285 geometric mean titers
Interval 228.9 to 354.3
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 19A
|
339 geometric mean titers
Interval 296.4 to 386.9
|
200 geometric mean titers
Interval 170.0 to 234.4
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 23F
|
310 geometric mean titers
Interval 254.1 to 378.0
|
43 geometric mean titers
Interval 34.2 to 53.5
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 1
|
76 geometric mean titers
Interval 64.9 to 89.5
|
55 geometric mean titers
Interval 46.2 to 64.8
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 3
|
55 geometric mean titers
Interval 47.9 to 62.0
|
49 geometric mean titers
Interval 42.9 to 56.9
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 4
|
472 geometric mean titers
Interval 383.5 to 580.2
|
203 geometric mean titers
Interval 157.1 to 262.2
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 18C
|
975 geometric mean titers
Interval 829.0 to 1147.3
|
481 geometric mean titers
Interval 385.1 to 600.7
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Serotype 19F
|
311 geometric mean titers
Interval 257.1 to 375.9
|
214 geometric mean titers
Interval 174.3 to 262.8
|
SECONDARY outcome
Timeframe: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1Population: Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the given serotype.
Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.
Outcome measures
| Measure |
13vPnC
n=366 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=433 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
|
1134 geometric mean titer
Interval 943.6 to 1363.7
|
94 geometric mean titer
Interval 74.1 to 118.5
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0Population: Safety population is all participants who receive at least 1 dose of study vaccine. N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC and 23vPS (Vax 1). Participants may be represented in more than 1 category.
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Outcome measures
| Measure |
13vPnC
n=370 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=387 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Redness: Any (n=306, 324)
|
10.8 percentage of participants
|
22.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Redness: Mild (n=304, 311)
|
9.5 percentage of participants
|
13.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Redness: Moderate (n=301, 314)
|
4.7 percentage of participants
|
11.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Redness: Severe (n=299, 310)
|
1.7 percentage of participants
|
4.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Swelling: Mild (n=305, 315)
|
8.9 percentage of participants
|
14.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Swelling: Moderate (n=299, 323)
|
4.0 percentage of participants
|
13.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Swelling: Severe (n=297, 310)
|
0.0 percentage of participants
|
4.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Pain: Any (n=362, 383)
|
51.7 percentage of participants
|
58.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Pain: Mild (n=359, 377)
|
50.1 percentage of participants
|
54.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Pain: Moderate (n=306, 330)
|
7.5 percentage of participants
|
23.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Pain: Severe (n=299, 306)
|
1.3 percentage of participants
|
2.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Swelling: Any (n=307, 333)
|
10.4 percentage of participants
|
23.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Limitation of arm movement: Any (n=313, 326)
|
10.5 percentage of participants
|
27.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Limitation of arm movement: Mild (n=312, 322)
|
10.3 percentage of participants
|
25.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Limitation of arm movement: Moderate (n=297, 303)
|
0.3 percentage of participants
|
2.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Limitation of arm movement: Severe (n=298, 305)
|
0.7 percentage of participants
|
3.0 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Outcome measures
| Measure |
13vPnC
n=265 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=265 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Mild (n=182, 182)
|
8.2 percentage of participants
|
6.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Moderate (n=182, 182)
|
4.4 percentage of participants
|
7.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Mild (n=251, 251)
|
53.0 percentage of participants
|
54.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Any (n=185, 185)
|
9.7 percentage of participants
|
12.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Severe (n=179, 179)
|
1.1 percentage of participants
|
1.7 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Any (n=185, 185)
|
9.2 percentage of participants
|
10.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Mild (n=182, 182)
|
6.6 percentage of participants
|
8.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Moderate (n=179, 179)
|
3.4 percentage of participants
|
2.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Severe (n=177, 177)
|
0.0 percentage of participants
|
0.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Any (n=258, 258)
|
55.0 percentage of participants
|
57.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Moderate (n=187, 187)
|
8.6 percentage of participants
|
11.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Severe (n=179, 179)
|
1.7 percentage of participants
|
0.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Any (n=195, 195)
|
9.7 percentage of participants
|
13.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Mild (n=194, 194)
|
9.3 percentage of participants
|
13.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Moderate (n=178, 178)
|
0.6 percentage of participants
|
0.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Severe (n=178, 178)
|
0.6 percentage of participants
|
0.0 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 23vPS (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Outcome measures
| Measure |
13vPnC
n=387 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=304 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Severe (n=310, 227)
|
4.8 percentage of participants
|
1.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Any (n=333, 236)
|
23.1 percentage of participants
|
12.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Any (n=324, 236)
|
22.2 percentage of participants
|
12.7 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Mild (n=311, 233)
|
13.5 percentage of participants
|
6.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Redness: Moderate (n=314, 231)
|
11.5 percentage of participants
|
6.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Mild (n=315, 234)
|
14.0 percentage of participants
|
10.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Moderate (n=323, 229)
|
13.6 percentage of participants
|
3.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Swelling: Severe (n=310, 227)
|
4.8 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Any (n=383, 297)
|
58.5 percentage of participants
|
58.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Mild (n=377, 291)
|
54.1 percentage of participants
|
54.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Moderate (n=330, 239)
|
23.6 percentage of participants
|
13.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Pain: Severe (n=306, 226)
|
2.3 percentage of participants
|
0.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Any (n=326, 247)
|
27.6 percentage of participants
|
16.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Mild (n=322, 245)
|
25.2 percentage of participants
|
15.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Moderate (n=303, 228)
|
2.6 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Severe (n=305, 228)
|
3.0 percentage of participants
|
0.9 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC / 13vPnC and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Outcome measures
| Measure |
13vPnC
n=304 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=311 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Limitation of arm movement: Mild (n=245, 249)
|
15.5 percentage of participants
|
18.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Limitation of arm movement: Severe (n=228, 222)
|
0.9 percentage of participants
|
1.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Redness: Any (n=236, 228)
|
12.7 percentage of participants
|
10.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Redness: Mild (n=233, 226)
|
6.9 percentage of participants
|
8.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Redness: Moderate (n=231, 223)
|
6.9 percentage of participants
|
3.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Redness: Severe (n=227, 222)
|
1.8 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Swelling: Any (n=236, 241)
|
12.3 percentage of participants
|
14.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Swelling: Mild (n=234, 236)
|
10.3 percentage of participants
|
11.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Swelling: Moderate (n=229, 229)
|
3.5 percentage of participants
|
4.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Swelling: Severe (n=227, 222)
|
0.9 percentage of participants
|
0.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Pain: Any (n=297, 302)
|
58.2 percentage of participants
|
56.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Pain: Mild (n=291, 297)
|
54.3 percentage of participants
|
53.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Pain: Moderate (n=239, 236)
|
13.0 percentage of participants
|
13.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Pain: Severe (n=226, 221)
|
0.4 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Limitation of arm movement: Any (n=247, 251)
|
16.2 percentage of participants
|
19.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Limitation of arm movement: Moderate (n=228, 222)
|
0.9 percentage of participants
|
0.9 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any local reaction reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Outcome measures
| Measure |
13vPnC
n=370 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=311 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Redness: Any (n=306, 228)
|
10.8 percentage of participants
|
10.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Redness: Moderate (n=301, 223)
|
4.7 percentage of participants
|
3.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Redness: Severe (n=299, 222)
|
1.7 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Swelling: Mild (n=305, 236)
|
8.9 percentage of participants
|
11.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Pain: Mild (n=359, 297)
|
50.1 percentage of participants
|
53.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Severe (n=298, 222)
|
0.7 percentage of participants
|
1.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Redness: Mild (n=304, 226)
|
9.5 percentage of participants
|
8.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Swelling: Any (n=307, 241)
|
10.4 percentage of participants
|
14.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Swelling: Moderate (n=299, 229)
|
4.0 percentage of participants
|
4.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Swelling: Severe (n=297, 222)
|
0.0 percentage of participants
|
0.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Pain: Any (n=362, 302)
|
51.7 percentage of participants
|
56.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Pain: Moderate (n=306, 236)
|
7.5 percentage of participants
|
13.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Pain: Severe (n=299, 221)
|
1.3 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Any (n=313, 251)
|
10.5 percentage of participants
|
19.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Mild (n=312, 249)
|
10.3 percentage of participants
|
18.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Limitation of arm movement: Moderate (n=297, 222)
|
0.3 percentage of participants
|
0.9 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0Population: Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC and 23vPS (Year 0). Participants may be represented in more than 1 category.
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Outcome measures
| Measure |
13vPnC
n=388 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=403 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Fever: Any ≥38 degrees C (n=299, 309)
|
1.0 percentage of participants
|
4.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Fever: Severe ≥39 but ≤40 degrees C (n=297, 301)
|
0.0 percentage of participants
|
0.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Headache (n=329, 331)
|
23.7 percentage of participants
|
26.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Chills (n=305, 312)
|
7.9 percentage of participants
|
11.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Fever: Mild ≥38 but <38.5 degrees C (n=299, 303)
|
1.0 percentage of participants
|
2.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Fever: Moderate ≥38.5 but <39 degrees C(n=297,301)
|
0.0 percentage of participants
|
0.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Potentially life-threatening >40C (n=297, 307)
|
0.0 percentage of participants
|
2.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Fatigue (n=350, 367)
|
34.0 percentage of participants
|
43.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Rash (n=303, 323)
|
7.3 percentage of participants
|
16.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Vomiting (n=300, 304)
|
1.7 percentage of participants
|
1.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Decreased appetite (n=317, 313)
|
10.4 percentage of participants
|
11.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
New muscle pain (n=345, 358)
|
36.8 percentage of participants
|
44.7 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Aggravated muscle pain (n=320, 334)
|
20.6 percentage of participants
|
27.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
New joint pain (n=310, 323)
|
12.6 percentage of participants
|
14.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Aggravated joint pain (n=310, 322)
|
11.6 percentage of participants
|
16.5 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Outcome measures
| Measure |
13vPnC
n=259 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=259 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Headache (n=200, 200)
|
23.0 percentage of participants
|
19.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Any ≥38 degrees C (n=179, 179)
|
1.7 percentage of participants
|
2.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Mild ≥38 but <38.5 degrees C (n=179, 179)
|
1.7 percentage of participants
|
0.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Moderate ≥38.5 but <39 degrees C(n=177,177)
|
0.0 percentage of participants
|
0.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Severe ≥39 but ≤40 degrees C (n=177, 177)
|
0.0 percentage of participants
|
0.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Potentially life-threatening >40C (n=177, 177)
|
0.0 percentage of participants
|
1.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fatigue (n=215, 215)
|
33.5 percentage of participants
|
28.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Chills (n=182, 182)
|
9.3 percentage of participants
|
4.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Rash (n=183, 183)
|
8.2 percentage of participants
|
6.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Vomiting (n=178, 178)
|
1.1 percentage of participants
|
0.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Decreased appetite (n=190, 190)
|
8.4 percentage of participants
|
7.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
New muscle pain (n=219, 219)
|
37.9 percentage of participants
|
35.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Aggravated muscle pain (n=198, 198)
|
20.7 percentage of participants
|
16.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
New joint pain (n=187, 187)
|
11.2 percentage of participants
|
7.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Aggravated joint pain (n=188, 188)
|
11.2 percentage of participants
|
10.1 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 23vPS (Year 0) and 13vPnC / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Outcome measures
| Measure |
13vPnC
n=403 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=290 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Any ≥38 degrees C (n=309, 229)
|
4.2 percentage of participants
|
3.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Mild ≥38 but <38.5 degrees C (n=303, 227)
|
2.0 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Moderate ≥38.5 but <39 degrees C(n=301,227)
|
0.0 percentage of participants
|
0.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fever: Severe ≥39 but ≤40 degrees C (n=301, 226)
|
0.3 percentage of participants
|
0.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Potentially life-threatening >40C (n=307, 227)
|
2.0 percentage of participants
|
1.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Fatigue (n=367, 255)
|
43.3 percentage of participants
|
28.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Headache (n=331, 246)
|
26.0 percentage of participants
|
19.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Chills (n=312, 234)
|
11.2 percentage of participants
|
7.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Rash (n=323, 232)
|
16.4 percentage of participants
|
6.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Vomiting (n=304, 226)
|
1.3 percentage of participants
|
0.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Decreased appetite (n=313, 237)
|
11.5 percentage of participants
|
8.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
New muscle pain (n=358, 260)
|
44.7 percentage of participants
|
34.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Aggravated muscle pain (n=334, 245)
|
27.5 percentage of participants
|
18.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
New joint pain (n=323, 238)
|
14.9 percentage of participants
|
10.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Aggravated joint pain (n=322, 239)
|
16.5 percentage of participants
|
12.6 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC / 13vPnC and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Outcome measures
| Measure |
13vPnC
n=290 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=299 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Aggravated joint pain (n=239, 231)
|
12.6 percentage of participants
|
11.7 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Rash (n=232, 226)
|
6.0 percentage of participants
|
7.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Any ≥38 degrees C (n=229, 224)
|
3.5 percentage of participants
|
2.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Mild ≥38 but <38.5 degrees C (n=227, 224)
|
0.9 percentage of participants
|
1.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Moderate ≥38.5 but <39 degrees C(n=227,221)
|
0.9 percentage of participants
|
0.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Severe ≥39 but ≤40 degrees C (n=226, 222)
|
0.4 percentage of participants
|
0.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Potentially life-threatening >40C (n=227, 221)
|
1.3 percentage of participants
|
0.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Fatigue (n=255, 265)
|
28.6 percentage of participants
|
34.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Headache (n=246, 248)
|
19.1 percentage of participants
|
22.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Chills (n=234, 233)
|
7.3 percentage of participants
|
9.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Vomiting (n=226, 226)
|
0.4 percentage of participants
|
3.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Decreased appetite (n=237, 230)
|
8.9 percentage of participants
|
7.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
New muscle pain (n=260, 263)
|
34.6 percentage of participants
|
35.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Aggravated muscle pain (n=245, 248)
|
18.0 percentage of participants
|
21.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
New joint pain (n=238, 234)
|
10.5 percentage of participants
|
12.0 percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1Population: Safety population; N=number of participants who reported any systemic reactogenicity events; (n)=number of participants with known values for 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1). Participants may be represented in more than 1 category.
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Outcome measures
| Measure |
13vPnC
n=388 Participants
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
|
23vPS
n=299 Participants
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
|
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Potentially life-threatening >40C (n=297, 221)
|
0.0 percentage of participants
|
0.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Any ≥38 degrees C (n=299, 224)
|
1.0 percentage of participants
|
2.2 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Mild ≥38 but <38.5 degrees C (n=299, 224)
|
1.0 percentage of participants
|
1.8 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Moderate ≥38.5 but <39 degrees C(n=297,221)
|
0.0 percentage of participants
|
0.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Fever: Severe ≥39 but ≤40 degrees C (n=297, 222)
|
0.0 percentage of participants
|
0.5 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Fatigue (n=350, 265)
|
34.0 percentage of participants
|
34.3 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Headache (n=329, 248)
|
23.7 percentage of participants
|
22.6 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Chills (n=305, 233)
|
7.9 percentage of participants
|
9.9 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Rash (n=303, 226)
|
7.3 percentage of participants
|
7.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Vomiting (n=300, 226)
|
1.7 percentage of participants
|
3.1 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Decreased appetite (n=317, 230)
|
10.4 percentage of participants
|
7.4 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
New muscle pain (n=345, 263)
|
36.8 percentage of participants
|
35.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Aggravated muscle pain (n=320, 248)
|
20.6 percentage of participants
|
21.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
New joint pain (n=310, 234)
|
12.6 percentage of participants
|
12.0 percentage of participants
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Aggravated joint pain (n=310, 231)
|
11.6 percentage of participants
|
11.7 percentage of participants
|
Adverse Events
13vPnC (Vax 1 / Year 0) 1 Month After Vaccination
Serious events: 3 serious events
Other events: 234 other events
Deaths: 0 deaths
23vPS (Vax 1 / Year 0) 1 Month After Vaccination
Serious events: 8 serious events
Other events: 275 other events
Deaths: 0 deaths
13vPnC 6-M FU (Vax 1 / Year 0)
Serious events: 27 serious events
Other events: 60 other events
Deaths: 0 deaths
23vPS 6-M FU (Vax 1 / Year 0)
Serious events: 26 serious events
Other events: 59 other events
Deaths: 0 deaths
13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination
Serious events: 4 serious events
Other events: 191 other events
Deaths: 0 deaths
23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination
Serious events: 7 serious events
Other events: 189 other events
Deaths: 0 deaths
13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)
Serious events: 17 serious events
Other events: 29 other events
Deaths: 0 deaths
23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)
Serious events: 21 serious events
Other events: 30 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
13vPnC (Vax 1 / Year 0) 1 Month After Vaccination
n=463 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=66; systematic (solicited) Local Reactions N=209; systematic (solicited) Systemic Events N=234.
|
23vPS (Vax 1 / Year 0) 1 Month After Vaccination
n=473 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=83; systematic (solicited) Local Reactions N=248; systematic (solicited) Systemic Events N=275.
|
13vPnC 6-M FU (Vax 1 / Year 0)
n=463 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1); events assessed at 6-Month Follow-up visit (6-M FU) (Vax 1 / Year 0) telephone visit to report new events.
|
23vPS 6-M FU (Vax 1 / Year 0)
n=473 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1); events assessed at 6-M FU (Vax 1 / Year 0) telephone visit to report new events.
|
13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination
n=391 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=69; systematic (solicited) Local Reactions N=191; systematic (solicited) Systemic Events N=161.
|
23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination
n=404 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=62; systematic (solicited) Local Reactions N=189; systematic (solicited) Systemic Events N=174.
|
13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)
n=391 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2) ; events assessed at 6-M FU (Vax 2 / Year 1) telephone visit to report new events.
|
23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)
n=404 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose at Year 1 (Vax 2); events assessed at 6-M FU (Vax 2 / Year 1) telephone visit to report new events.
|
|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Idiopathic thrombocytopenic purpura
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Angina pectoris
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.65%
3/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Atrial fibrillation
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.74%
3/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Atrial flutter
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Diastolic dysfunction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Sick sinus syndrome
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Sinus arrest
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Abdominal mass
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Colonic stenosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Small intestinal haemorrhage
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Diverticular perforation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Subileus
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Asthenia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Device related infection
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Labyrinthitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Streptococcal bacteraemia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Appendicitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Gangrene
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Pneumonia primary atypical
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Post procedural pulmonary embolism
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Monarthritis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.65%
3/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.85%
4/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.77%
3/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma recurrent
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma of the skin
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer in situ
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal tract adenoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer metastatic
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Syncope
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Neurogenic bladder
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Uterovaginal prolapse
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive airways disorder
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Orthopnoea
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Aortic aneurysm
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Hypertension
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
Other adverse events
| Measure |
13vPnC (Vax 1 / Year 0) 1 Month After Vaccination
n=463 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=66; systematic (solicited) Local Reactions N=209; systematic (solicited) Systemic Events N=234.
|
23vPS (Vax 1 / Year 0) 1 Month After Vaccination
n=473 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=83; systematic (solicited) Local Reactions N=248; systematic (solicited) Systemic Events N=275.
|
13vPnC 6-M FU (Vax 1 / Year 0)
n=463 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1); events assessed at 6-Month Follow-up visit (6-M FU) (Vax 1 / Year 0) telephone visit to report new events.
|
23vPS 6-M FU (Vax 1 / Year 0)
n=473 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1); events assessed at 6-M FU (Vax 1 / Year 0) telephone visit to report new events.
|
13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination
n=391 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=69; systematic (solicited) Local Reactions N=191; systematic (solicited) Systemic Events N=161.
|
23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination
n=404 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2)
Other Adverse Events (non-serious events): the number affected (N) for nonsystematic (unsolicited) Other Adverse Events N=62; systematic (solicited) Local Reactions N=189; systematic (solicited) Systemic Events N=174.
|
13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1)
n=391 participants at risk
13vPnC 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose IM at Year 1 (Vax 2) ; events assessed at 6-M FU (Vax 2 / Year 1) telephone visit to report new events.
|
23vPS / 13vPnC 6-M FU (Vax 2 / Year 1)
n=404 participants at risk
23vPS 0.5 mL dose IM at Year 0 (Vax 1) and 13vPnC 0.5 mL dose at Year 1 (Vax 2); events assessed at 6-M FU (Vax 2 / Year 1) telephone visit to report new events.
|
|---|---|---|---|---|---|---|---|---|
|
Endocrine disorders
Hyperparathyroidism
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Conjunctivitis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Eye discharge
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Eye pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Hypertensive heart disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Cardiac disorders
Sick sinus syndrome
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Cerumen impaction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Ear pain
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Deafness
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Deafness neurosensory
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Ear and labyrinth disorders
Ear discomfort
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Endocrine disorders
Goitre
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Vision blurred
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Cataract
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Macular degeneration
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Hypermetropia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Astigmatism
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Keratitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Presbyopia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Eye disorders
Open angle glaucoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.86%
4/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.99%
4/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Colonic polyp
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Diverticulum
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Dysphagia
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Melaena
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Nausea
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Toothache
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Barrett's oesophagus
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Coeliac disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Gastric mucosal lesion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Gastric polyps
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Oesophageal ulcer
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Faecal incontinence
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Gastrointestinal disorders
Swollen tongue
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site pruritus
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fatigue
|
33.5%
72/215 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
28.4%
61/215 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site induration
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site movement impairment
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Oedema peripheral
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Chest discomfort
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site erythema
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site haematoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.77%
3/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.74%
3/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site mass
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Vaccination site haematoma
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Vaccination site pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Cyst
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Gait disturbance
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Inflammation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Influenza like illness
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Injection site reaction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Local swelling
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Pyrexia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Immune system disorders
Allergy to arthropod sting
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Upper respiratory tract infection
|
2.2%
10/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
1.3%
6/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.77%
3/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
1.7%
7/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Bronchitis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Urinary tract infection
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.77%
3/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Eye infection
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Labyrinthitis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Acute sinusitis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Borrelia infection
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Sinusitis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Tinea cruris
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Vulvovaginal candidiasis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Wound infecton
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Genital herpes
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Cystitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Skin infection
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Foreign body in eye
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Joint sprain
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Meniscus lesion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Back injury
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Factured sacrum
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Skin injury
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Arthropod bite
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Excoriation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Arthropod sting
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Open wound
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Alanine aminotransferase increased
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Aspartate aminotransferase increased
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Biopsy skin
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Blood parathyroid hormone increased
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Heart rate irregular
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Prostatic specific antigen increased
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Blood glucose increased
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Occult blood positive
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Red blood cell sedimentation rate increased
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Investigations
Blood pressure increased
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Gout
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.65%
3/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Diabetic foot
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Type I diabetes mellitus
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Metabolism and nutrition disorders
Fluid retention
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.65%
3/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.85%
4/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.74%
3/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Monarthritis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.42%
2/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Pelvic deformity
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Osteopenia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Sacroiliitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign breast neoplasm
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thyroid gland
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Dizziness
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Headache
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Balance disorder
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Sinus headache
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Anosmia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Dementia alzheimer's type
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Senile dementia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Hemianopia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Narcolepsy
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Hypertonia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Migraine
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Nervous system disorders
Post herpetic neuralgia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Psychiatric disorders
Depression
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Psychiatric disorders
Nervousness
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Hypertonic bladder
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Renal artery occlusion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Renal failure chronic
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Urethral stenosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Bladder spasm
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Renal artery arteriosclerosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Bladder neck obstruction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Renal and urinary disorders
Stress urinary incontinence
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Breast mass
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Breast calcification
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.77%
3/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.99%
4/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.50%
2/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.74%
3/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Diaphragmatic hernia
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract congestion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial hyperreactivity
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum perforation
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
1.3%
6/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.43%
2/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Campbell de Morgan spots
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Cutis laxa
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Eczema nummular
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Eczema asteatotic
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Lichenoid keratosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Rosacea
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Skin wrinkling
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Pruritus generalising
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Hypertension
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.65%
3/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.63%
3/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.51%
2/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Flushing
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Hypotension
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Aortic disorder
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.22%
1/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Vasoconstriction
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Venous insufficiency
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.21%
1/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Haematoma
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.25%
1/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/463 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.26%
1/391 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Redness (Any)
|
9.7%
18/185 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
12.4%
23/185 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Redness (Mild)
|
8.2%
15/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
6.0%
11/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Redness (Moderate)
|
4.4%
8/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
7.1%
13/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Redness (Severe)
|
1.1%
2/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
1.7%
3/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Swelling (Any)
|
9.2%
17/185 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
10.8%
20/185 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Swelling (Mild)
|
6.6%
12/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
8.8%
16/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Swelling (Moderate)
|
3.4%
6/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
2.8%
5/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Swelling (Severe)
|
0.00%
0/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Pain (Any)
|
55.0%
142/258 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
57.4%
148/258 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Pain (Mild)
|
53.0%
133/251 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
54.2%
136/251 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Pain (Moderate)
|
8.6%
16/187 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
11.2%
21/187 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Pain (Severe)
|
1.7%
3/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.56%
1/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Limitation of arm movement (Any)
|
9.7%
19/195 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
13.3%
26/195 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Limitation of arm movement (Mild)
|
9.3%
18/194 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
13.4%
26/194 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Limitation of arm movement (Moderate)
|
0.56%
1/178 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.56%
1/178 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
Skin and subcutaneous tissue disorders
Limitation of arm movement (Severe)
|
0.56%
1/178 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/178 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fever (Any) ≥ 38 degrees Celsius (C)
|
1.0%
3/299 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
4.2%
13/309 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
3.5%
8/229 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
2.2%
5/224 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fever (Mild) ≥ 38 degrees but < 38.5 degrees C
|
1.7%
3/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.56%
1/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fever (Moderate) ≥ 38.5 degrees but < 39 degrees C
|
0.00%
0/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fever (Severe) ≥ 39 degrees but ≤ 40 degrees C
|
0.00%
0/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.56%
1/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fever (Potentially life threatening) > 40 degrees C
|
0.00%
0/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
1.1%
2/177 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Headache
|
23.0%
46/200 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
19.0%
38/200 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Chills
|
9.3%
17/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
4.4%
8/182 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Rash
|
8.2%
15/183 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
6.0%
11/183 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Vomiting
|
1.1%
2/178 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/178 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Decreased appetite
|
8.4%
16/190 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
7.9%
15/190 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
New generalized muscle pain
|
37.9%
83/219 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
35.6%
78/219 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Aggravated generalized muscle pain
|
20.7%
41/198 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
16.2%
32/198 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
New generalized joint pain
|
11.2%
21/187 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
7.5%
14/187 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Aggravated generalized joint pain
|
11.2%
21/188 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
10.1%
19/188 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
|
General disorders
Fever (Any) ≥ 38 degrees C
|
1.7%
3/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/473 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
2.2%
4/179 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
0.00%
0/404 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
—
0/0 • Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.
Same event may appear as both an AE and SAE; however, are distinct events. Event may be categorized as serious in 1 subject and nonserious in another, or 1 subject may have experienced both a serious and nonserious event during study. Zero in denominator (0 participants at risk) indicates Reporting Group was not systematically assessed for AE term.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER